Locus CEO Nishith Rastogi Wants His AI Tool To Help Meet Customer Demands

Consumer behavior continues to change in the wake of the pandemic. One trend found by 6 River Systems is that consumers demand “omnichannel” retail experiences that are consistent across channels. It can be very difficult for retailers to bridge the gap between brick-and-motor and online delivery of their products.

How can retailers create seamless experiences when the logistics are so difficult?

This is where AI tools can step into the picture. Host Melissa Gonzalez interviews Nishith Rastogi, CEO and Founder of Locus, on today’s episode of Retail Refined to find delivery solutions for retailers. Locus provides software solutions that can help retailers meet both environmental regulations and meet customer desires. His company prides itself on helping retail clients, like Unilever, replicate their brick-and-motor experiences before packages are delivered to their doorstep.

Nishith explains how Locus’s cloud-based software:

  • Adapt to on-the-ground logistic problems
  • Assess data to design strategies that are both cost-effective and climate-friendly
  • Find tangible ways to optimize CX

Nishith has witnessed firsthand the shifts in consumer expectations. He attributes the acceleration of these changes to the pandemic. “My parents are now avid e-commerce customers. At this point, investing in the Last-mile is critical to retain these customers because clients expect it, ” Nishith says.

Nishith is the CEO and founder of Locus and drives business strategy and innovation at the company. He is responsible for business expansion across geographies and heads operations globally. Prior to founding Locus, he worked with Amazon, building algorithms to counter credit card fraud. He also co-founded PinChat, a location-based conversation platform. Nishith holds a Bachelor’s degree in Electronics and a Master’s in Economics from BITS Pilani. He is a published author in the field of experimental physics and has patents in Machine Learning.

Listen to Retail Refined on MarketScale or wherever you find your favorite podcasts.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More